Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.
about
Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling.PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptorTargeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in micePPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1PPARs and the cardiovascular systemRole of Peroxisome Proliferator-Activated Receptors in Inflammation ControlThe peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol esterPPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsThe Interaction between Fluid Wall Shear Stress and Solid Circumferential Strain Affects Endothelial Gene ExpressionThe role of fatty acid binding proteins in metabolic syndrome and atherosclerosisComparative proteome analysis of TGF-beta1-induced fibrosis processes in normal rat kidney interstitial fibroblast cells in response to ascofuranoneAssociation between peroxisome proliferator-activated receptor-alpha, delta, and gamma polymorphisms and risk of coronary heart disease: A case-control study and meta-analysisThe good fat hormone: adiponectin and cardiovascular disease.The impact of bubbles on measurement of drug release from echogenic liposomesPharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes.Transcription of human resistin gene involves an interaction of Sp1 with peroxisome proliferator-activating receptor gamma (PPARgamma)Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.Activation of peroxisome proliferator-activated receptor gamma by human cytomegalovirus for de novo replication impairs migration and invasiveness of cytotrophoblasts from early placentas.Is spaceflight-induced immune dysfunction linked to systemic changes in metabolism?Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus.Peroxisome proliferator-activated receptors in the cardiovascular system.Current, new and future treatments in dyslipidaemia and atherosclerosis.PPAR agonists as direct modulators of the vessel wall in cardiovascular disease.Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infectionDe novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific.Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempolPeroxisome proliferator-activated receptor-gamma: too much of a good thing causes harmVascular smooth muscle cell peroxisome proliferator-activated receptor-γ deletion promotes abdominal aortic aneurysmsConditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.Lack of PPARγ in myeloid cells confers resistance to Listeria monocytogenes infection.Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasiaPeroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.Peroxisome proliferator-activated receptor gamma and atherosclerosis.Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging.
P2860
Q21245560-2BED3DED-4E9D-4C78-A3D9-188D69CD305AQ24300059-F7054D27-8A5F-424B-A8C0-B2690B8BC95EQ24623151-C284F89F-EE45-49DD-829C-7FE6BBC24F2FQ24633440-1C88C7E8-2E0B-485C-BCCA-256A5306DF55Q24642728-9FE51701-A8A3-4941-83E3-833E4045962BQ24796541-07268B3B-6823-465D-A8B2-F03E42DC34EDQ24806798-8FBC7E81-3BCD-4927-B257-4D1946DF1729Q26738811-F1039E9F-98D0-4EC6-8A32-F65BA929E8F1Q26829098-25693C56-2EB4-496B-8669-96C3688A60DDQ27304516-3799F607-0713-4D2B-AF4B-AAC31084910EQ28271189-ADE379F0-5332-479A-BFD1-B60CDE5E5820Q28574899-78FC3951-EC5D-4A07-9B3F-572D8F7E7748Q30248537-7F5A8DB6-622D-40CA-88E1-A2694C907E6AQ30353178-32DC5BD8-0265-4633-A12C-F0310DACA398Q30435860-7F282E14-EABA-46E4-AAF2-B80AC4552707Q30977623-EB52F44A-9D44-4701-89AE-9A78783FA5F1Q33548739-1EB2C0D0-2D6D-4478-8762-13C437030893Q33585657-8DD0F65F-7283-4A88-A1D6-C3908AFE3B4CQ33676613-E1FEDDBB-B111-4433-B8A6-99F88D462E3AQ33724786-3279CB99-C86A-4F31-8836-79639D833CACQ33780711-1CD36824-83BA-43E0-97B2-793FDFA53BF3Q33811239-69ACA765-CBAE-47B1-965E-894D2A18E75BQ33850995-481B9373-3F7F-4AC0-86A6-066C991F68AAQ33993678-99EDFEA0-72AA-4F03-A1A9-DE6EFAEFDD44Q33996831-62540B57-1988-49F6-B7F1-E983FAEC5FDFQ34086932-3130B68A-87F3-4555-A6F8-9E3C5403687FQ34093108-233672E5-79DE-4129-BF79-74E64145922CQ34107495-22D251DD-35A1-4369-BD8F-D975FA81430AQ34149341-FB89D834-A497-4EB4-9E8A-3EB29363CD86Q34165847-6D10C35F-F38E-423B-9DC0-2C5B58EF6478Q34172757-2690A046-ACFA-41F5-A163-E13E0E5DB62EQ34277079-AD87EB82-A14C-4FEB-82F4-0553B1775417Q34281850-AA8DB1BD-6492-4875-9780-8CE8599A759AQ34312164-72239106-B6F9-4E80-927C-F5FA16A14A63Q34342040-684D484E-41B9-45BA-8CA8-8ACB72789F68Q34479025-1706AFF1-A056-4ED0-A8CE-3EB29B8A2818Q34492831-0CBF0192-560C-490B-ABBB-EAFB3BB29AC5Q34509942-D8EE8AD1-C79D-4F86-BB1D-7D9B06641D22Q34509964-EE30D713-798A-45FF-888C-54E3529B5F09Q34537454-506DB0DF-C009-43EC-9038-017464C43F14
P2860
Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@ast
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@en
type
label
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@ast
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@en
prefLabel
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@ast
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@en
P2093
P2860
P1476
Macrophages in human atheroma ...... nonuclear phagocytes in vitro.
@en
P2093
P2860
P356
10.1016/S0002-9440(10)65540-X
P407
P577
1998-07-01T00:00:00Z